{"id":3576,"date":"2020-08-04T05:30:09","date_gmt":"2020-08-04T09:30:09","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\/"},"modified":"2026-09-24T00:08:40","modified_gmt":"2026-09-24T04:08:40","slug":"gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2020\/08\/04\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\/","title":{"rendered":"GenSight Biologics tire la seconde tranche obligataire de 4 millions d\u2019euros de Kreos Capital"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Paris, France, le 4 ao\u00fbt 2020, 7h30 CEST <\/strong>\u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME) (la <strong>\u00ab\u00a0Soci\u00e9t\u00e9\u00a0\u00bb<\/strong> ou <strong>\u00ab\u00a0GenSight\u00a0\u00bb<\/strong>), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui avoir \u00e9mis une demande de tirage de la Tranche B dans le cadre de son emprunt obligataire avec Kreos Capital.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L\u2019accord de financement obligataire avec Kreos Capital, conclu en d\u00e9cembre 2019, pr\u00e9voyait une \u00e9mission d&rsquo;obligations simples de 10 millions d&rsquo;euros structur\u00e9e en deux tranches de 6 millions d&rsquo;euros et, sous r\u00e9serve d&rsquo;un financement \u00e9ligible, de 4 millions d&rsquo;euros (dont 30% de chaque tranche pouvant \u00eatre \u00e9mis sous forme d&rsquo;obligations convertibles \u00e0 l&rsquo;option de Kreos). Chaque tranche comprenait une \u00e9mission simultan\u00e9e de bons de souscription d&rsquo;actions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La Soci\u00e9t\u00e9 a tir\u00e9 la premi\u00e8re tranche de 6 millions d\u2019euros en d\u00e9cembre 2019, comprenant une \u00e9mission d&rsquo;obligations simples d&rsquo;un montant de 4,2 millions d&rsquo;euros et une \u00e9mission d&rsquo;obligations convertibles de 1,8 millions d&rsquo;euros.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Par la suite, comme d\u00e9crit dans son communiqu\u00e9 de presse du 9 juillet 2020, GenSight a modifi\u00e9 certains termes et conditions de la seconde tranche de 4 millions d\u2019euros pr\u00e9vue dans le cadre de son accord de financement obligataire (la <strong>\u00ab\u00a0Tranche B\u00a0\u00bb<\/strong>). En vertu de ces modifications, les parties ont reconnu l&rsquo;octroi d\u2019un Pr\u00eat Garanti par l\u2019Etat fran\u00e7ais (PGE) de 7 millions d\u2019euros, ainsi que certains revenus attendus des Autorisations Temporaires d\u2019Utilisation (ATU) en France, et ont convenu que la Tranche B pourrait \u00eatre tir\u00e9e plus t\u00f4t et dans des conditions plus souples. Bien que le montant total de 4 millions d\u2019euros pour la Tranche B soit rest\u00e9 inchang\u00e9, la proportion d\u2019obligations simples et convertibles a \u00e9t\u00e9 modifi\u00e9e afin d\u2019inclure des obligations convertibles suppl\u00e9mentaires et de r\u00e9duire d\u2019autant le nombre d\u2019obligations simples, comme d\u00e9crit plus en d\u00e9tail dans le communiqu\u00e9 de presse du 9 juillet 2020.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La Tranche B comprendra \u00e0 la fois une \u00e9mission d&rsquo;obligations simples de 2,5 millions d&rsquo;euros et une \u00e9mission d&rsquo;obligations convertibles de 1,5 million d&rsquo;euros. L&rsquo;\u00e9mission d&rsquo;obligations convertibles comprendra elle-m\u00eame 1 200 000 obligations convertibles initiales et 300 000 obligations convertibles suppl\u00e9mentaires d&rsquo;une valeur nominale de 0,01 \u20ac. Cela permettra \u00e0 Kreos de souscrire 534 521 actions \u00e0 un prix de conversion de 2,245 \u20ac, et 116 550 actions \u00e0 un prix de 2,574 \u20ac, respectivement.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Compte tenu du tirage de la Tranche B, et en incluant les pr\u00e9visions de revenus g\u00e9n\u00e9r\u00e9s par les ATUs en France, la Soci\u00e9t\u00e9 dispose d&rsquo;un fonds de roulement net suffisant pour faire face \u00e0 ses obligations jusqu&rsquo;\u00e0 mi-2021.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L&rsquo;accord avec Kreos Capital pr\u00e9voit \u00e9galement une \u00e9ventuelle troisi\u00e8me tranche de 2 millions d&rsquo;euros qui pourrait \u00eatre mise \u00e0 disposition \u00e0 une date ult\u00e9rieure.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c0 propos de GenSight\u00a0Biologics<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (<em>Mitochondrial Targeting Sequence<\/em>, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. Le candidat m\u00e9dicament le plus avanc\u00e9 de GenSight Biologics, LUMEVOQ<sup>\u00ae<\/sup> (GS010), est en Phase III pour le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), une maladie mitochondriale rare qui conduit \u00e0 une perte irr\u00e9versible de la vue chez les adolescents et les jeunes adultes. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intra-vitr\u00e9enne dans chaque \u0153il.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 4 ao\u00fbt 2020, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME) (la \u00ab\u00a0Soci\u00e9t\u00e9\u00a0\u00bb ou \u00ab\u00a0GenSight\u00a0\u00bb), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui avoir \u00e9mis une [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[76,80],"post-year":[],"class_list":["post-3576","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-type-corporate","news-type-finance"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics tire la seconde tranche obligataire de 4 millions d\u2019euros de Kreos Capital - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2020\/08\/04\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics tire la seconde tranche obligataire de 4 millions d\u2019euros de Kreos Capital - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 4 ao\u00fbt 2020, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME) (la \u00ab\u00a0Soci\u00e9t\u00e9\u00a0\u00bb ou \u00ab\u00a0GenSight\u00a0\u00bb), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui avoir \u00e9mis une [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2020\/08\/04\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-04T09:30:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:08:40+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/08\\\/04\\\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/08\\\/04\\\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics tire la seconde tranche obligataire de 4 millions d\u2019euros de Kreos Capital\",\"datePublished\":\"2020-08-04T09:30:09+00:00\",\"dateModified\":\"2026-09-24T04:08:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/08\\\/04\\\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\\\/\"},\"wordCount\":686,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/08\\\/04\\\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/08\\\/04\\\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\\\/\",\"name\":\"GenSight Biologics tire la seconde tranche obligataire de 4 millions d\u2019euros de Kreos Capital - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-08-04T09:30:09+00:00\",\"dateModified\":\"2026-09-24T04:08:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/08\\\/04\\\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/08\\\/04\\\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/08\\\/04\\\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics tire la seconde tranche obligataire de 4 millions d\u2019euros de Kreos Capital\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics tire la seconde tranche obligataire de 4 millions d\u2019euros de Kreos Capital - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2020\/08\/04\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics tire la seconde tranche obligataire de 4 millions d\u2019euros de Kreos Capital - GenSight Biologics","og_description":"Paris, France, le 4 ao\u00fbt 2020, 7h30 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME) (la \u00ab\u00a0Soci\u00e9t\u00e9\u00a0\u00bb ou \u00ab\u00a0GenSight\u00a0\u00bb), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui avoir \u00e9mis une [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2020\/08\/04\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\/","og_site_name":"GenSight Biologics","article_published_time":"2020-08-04T09:30:09+00:00","article_modified_time":"2026-09-24T04:08:40+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/08\/04\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/08\/04\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics tire la seconde tranche obligataire de 4 millions d\u2019euros de Kreos Capital","datePublished":"2020-08-04T09:30:09+00:00","dateModified":"2026-09-24T04:08:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/08\/04\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\/"},"wordCount":686,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/08\/04\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2020\/08\/04\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\/","name":"GenSight Biologics tire la seconde tranche obligataire de 4 millions d\u2019euros de Kreos Capital - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2020-08-04T09:30:09+00:00","dateModified":"2026-09-24T04:08:40+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/08\/04\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2020\/08\/04\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/08\/04\/gensight-biologics-tire-la-seconde-tranche-obligataire-de-4-millions-deuros-de-kreos-capital\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics tire la seconde tranche obligataire de 4 millions d\u2019euros de Kreos Capital"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3576"}],"version-history":[{"count":2,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3576\/revisions"}],"predecessor-version":[{"id":6641,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3576\/revisions\/6641"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3576"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3576"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3576"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3576"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}